MARGARET J. OXTOBY, M.D.; CLAIRE V. BROOME, M.D.; RICHARD R. FACKLAM, Ph.D.; ROBERT C. GOOD, Ph.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: We want to emphasize that the Centers for Disease Control (CDC) continues to welcome isolates of Streptococcus pneumoniae from persons who have previously received the pneumococcal vaccine (either the 14- or 23-valent formulation). Two groups of pneumococcal isolates are serotyped at the CDC. The first group consists of isolates from all patients with invasive pneumococcal disease; these isolates are sent in regularly by hospitals participating in the national pneumococcal surveillance system. This representative sample of isolates provides information on serotype distribution. The second group consists of isolates from vaccinated persons; a few of these are from the
OXTOBY MJ, BROOME CV, FACKLAM RR, GOOD RC. Pneumococcal Vaccine and Isolates for the Centers for Disease Control. Ann Intern Med. ;104:587. doi: 10.7326/0003-4819-104-4-587_3
Download citation file:
Published: Ann Intern Med. 1986;104(4):587.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use